U.S. Food Stock News

Millrose Properties (MRP) opened Q1 2026 with total revenue of US$194.9 million and basic EPS of US$0.74, while trailing 12 month revenue stood at US$712.7 million and EPS at US$2.79 as the company continued to build on its recent return to profitability. The company has seen revenue move from US$82.7 million in Q1 2025 to US$194.9 million in Q1 2026, with basic EPS shifting from US$0.39 to US$0.74 over the same period. This sets up a story where investors are weighing the earnings recovery...

Oscar Health (OSCR) has opened 2026 with a sharp swing into profitability in its latest quarter, posting Q1 revenue of about US$4.6 billion alongside basic EPS of US$2.28 on net income of roughly US$679 million, versus Q1 2025 revenue of about US$3.0 billion and EPS of US$1.10. Over the trailing twelve months to Q1 2026, revenue has moved from roughly US$9.2 billion to about US$13.3 billion, while EPS on the same basis shifted from US$0.11 to a small loss of US$0.14, highlighting how the...

Teradata (TDC) opened 2026 with Q1 revenue of US$444 million and basic EPS of US$3.60, against a backdrop of trailing 12 month revenue of US$1.69 billion and EPS of US$4.48, where earnings over that period are reported to have grown very strongly year over year. Over recent quarters, revenue has moved from US$409 million in Q4 2024 to US$418 million in Q1 2025 and US$421 million in Q4 2025, while quarterly EPS has ranged between roughly US$0.09 and US$0.46 before this latest jump. This sets...

Earnings and convertible notes set the stage for Ocugen stock Ocugen (OCGN) is back in focus after reporting first quarter 2026 results and closing a US$103.5 million convertible note offering, a combination that puts both its cash needs and capital structure in the spotlight. See our latest analysis for Ocugen. The recent 1 day share price return of 2.35% decline and 7 day share price return of 13.39% decline suggest some short term profit taking after the earnings release and convertible...

White Mountains Insurance Group (WTM) opened 2026 with Q1 revenue of US$517.8 million and a basic EPS loss of US$12.59. This compares with basic EPS of US$13.22 on revenue of US$577.8 million in Q1 2025. Trailing twelve month revenue is US$3.7 billion and basic EPS is US$423.13. Over recent quarters, revenue has ranged from US$358 million in Q4 2024 to US$1.6 billion in Q4 2025. Basic EPS has moved from a loss of US$50.16 in Q4 2024 to US$322.14 in Q4 2025. This context frames a Q1 2026 print...

Hyster-Yale (HY) opened Q1 2026 with revenue of US$795.2 million and a basic EPS loss of US$1.71, while over the trailing 12 months revenue totaled US$3.7 billion with a basic EPS loss of US$5.59. Over recent quarters, the company has seen revenue move from US$910.4 million and EPS of US$0.49 in Q1 2025 to US$923.2 million and an EPS loss of US$2.96 in Q4 2025, before landing at the latest Q1 2026 levels. For investors, these results keep the focus squarely on how quickly margins can...

Global Industrial (GIC) just opened Q1 2026 with revenue of US$350.4 million and basic EPS of US$0.40, setting the tone for its latest update on profitability. The company has seen revenue move from US$321 million and EPS of US$0.35 in Q1 2025 to US$350.4 million and EPS of US$0.40 in Q1 2026. Trailing 12 month EPS sits at US$1.90 on US$1.4 billion of revenue, giving a clearer read on earnings power over a full year. With trailing net income of US$73 million and a net margin that has ticked...

Royalty Pharma (RPRX) opened 2026 with Q1 revenue of US$631 million and basic EPS of US$0.69, alongside trailing twelve month revenue of about US$2.4 billion and EPS of US$1.93 that sit against a net profit margin of 33.9%. Over recent quarters the company has seen revenue move from US$568 million in Q1 2025 to US$631 million in Q1 2026, while quarterly EPS has ranged between US$0.07 and US$0.69. This sets up a results snapshot where forecast revenue and earnings growth meet a thinner margin...

Atlas Energy Solutions (AESI) opened Q1 2026 with revenue of US$265.6 million and a basic EPS loss of US$0.38, as net income excluding extra items came in at a loss of US$47.3 million. The company has seen quarterly revenue move from US$297.6 million in Q1 2025 to US$265.6 million in Q1 2026, while basic EPS shifted from a profit of US$0.01 to a loss of US$0.38 over the same period. This sets up a mixed read on top line scale versus bottom line pressure. For investors, the story in this print...

If you are wondering whether Live Nation Entertainment is priced for perfection or still has room to run, the recent share performance gives you a useful starting point. The stock last closed at US$167.82, with returns of 9.6% over the past week, 4.8% over the past month, 15.5% year to date, 25.1% over 1 year, 113.6% over 3 years and 115.4% over 5 years. Recent headlines have focused on Live Nation Entertainment's position in global live events and ticketing, including regulatory attention...

BlackLine (NasdaqGS:BL) opened Q1 2026 with revenue of US$183.2 million and basic EPS of US$0.14, setting a clear marker for how its profitability story is evolving. The company reported revenue of US$169.5 million in Q4 2024 and US$183.2 million in Q1 2026, while quarterly basic EPS has ranged from US$0.08 to US$0.90 over that period, giving investors a detailed look at how margins are being earned rather than assumed. See our full analysis for BlackLine. With the headline figures on the...

Elanco Animal Health (ELAN) opened 2026 with Q1 revenue of about US$1.4b and basic EPS of US$0.11, alongside net income of US$57m, setting a cleaner profit picture against a still loss-making trailing twelve months. Over that period, basic EPS stands at a US$0.49 loss on revenue of US$4.9b and a net loss of US$242m. Over recent quarters the company has seen quarterly revenue move from US$1.02b in Q4 2024 to US$1.19b in Q1 2025 and then to US$1.37b in Q1 2026. Quarterly basic EPS shifted from...

Chemours (CC) has kicked off Q1 2026 with revenue of US$1.4 billion, a basic EPS loss of US$0.19 and net income excluding extra items of a US$29 million loss, with trailing 12 month figures showing revenue of US$5.8 billion and a net loss of US$410 million or basic EPS of US$2.79. Over recent quarters the company has seen revenue move from US$1.37 billion in Q1 2025 to US$1.38 billion in Q4 2025 and now US$1.4 billion, while quarterly basic EPS has ranged from a loss of US$2.54 in Q2 2025 to...

Holley Q1 2026 headline results Holley (HLLY) opened 2026 with Q1 revenue of US$147.3 million and basic EPS of US$0.06, alongside net income of US$7.3 million, putting fresh quarterly profits in focus for investors watching the stock around US$2.87. The company has seen quarterly revenue move from US$153.0 million and EPS of US$0.02 in Q1 2025 to US$147.3 million and EPS of US$0.06 in Q1 2026. Meanwhile, trailing 12 month EPS shifted from a loss of US$0.20 in Q1 2025 to a profit of US$0.20 in...

Andersons (ANDE) opened 2026 with Q1 revenue of US$2.6b and basic EPS of US$0.98, alongside net income of US$33.2m. Over the trailing twelve months it has produced revenue of US$11.0b, basic EPS of US$3.78 and net income of US$128.6m. The company has seen quarterly revenue move between US$2.5b and US$3.1b and basic EPS range from roughly US$0.01 to US$1.98 over the past year. This performance feeds into a trailing net margin of 1.2%, which puts the focus on how efficiently each dollar of...

Neurocrine Biosciences (NBIX) opened 2026 with Q1 revenue of US$814.5 million and basic EPS of US$1.97, while trailing 12 month figures sit at US$3.1 billion of revenue and EPS of US$6.71, setting a firm earnings-season backdrop. The company has seen quarterly revenue move from US$572.6 million in Q1 2025 to US$814.5 million in Q1 2026, with basic EPS shifting from US$0.08 to US$1.97 over the same period. Earnings growth of 118.6% over the past year and forecast EPS growth of about 21.1% per...

Oncolytics Biotech reported new durability and response data for its pelareorep therapy in RAS-mutant MSS metastatic colorectal cancer. The pelareorep-based regimen outperformed historical benchmarks in second-line treatment, with longer median duration of response and higher objective response rates. The company has initiated enrollment in a Phase 2 randomized study and is in active discussions with the FDA on a potential accelerated approval pathway. For investors watching NasdaqCM:ONCY,...

Aurora Innovation (NasdaqGS:AUR) has signed its first commercial contract for fully driverless long haul trucking with McLane Company. The partnership will use autonomous trucks to run driverless routes in Texas for a major national distributor. Aurora plans to scale to 200 fully driverless trucks and broaden its US route network by year end. Aurora Innovation focuses on autonomous driving technology, with trucking as a key commercial application. The McLane agreement moves the company from...

Limbach Holdings (LMB) has kicked off Q1 2026 with revenue of US$138.9 million and basic EPS of US$0.37, alongside trailing 12 month EPS of US$2.85 on revenue of US$652.6 million. This helps frame the latest quarter against a broader earnings base. Over recent quarters the company has seen revenue move from US$133.1 million in Q1 2025 to a peak of US$186.9 million in Q4 2025, while basic EPS ranged from US$0.67 to US$1.06 over that stretch. This provides a clearer view of how the top line has...

Johnson Controls International (JCI) has just posted Q2 2026 results with revenue of US$6.1b and basic EPS of US$1.00, set against trailing twelve month revenue of US$24.4b and EPS of US$3.26 that frame the latest quarter within a broader run of profitability. Over recent periods, the company has seen quarterly revenue move from US$5.7b in Q2 2025 to US$6.1b in Q2 2026, while basic EPS has shifted from US$0.72 to US$1.00, giving investors a clearer view of how the top and bottom lines are...

Westlake Chemical Partners (WLKP) opened 2026 with Q1 revenue of US$305.7 million and basic EPS of US$0.40, alongside trailing 12 month revenue of about US$1.2 billion and EPS of US$1.64 that reflect 6.7% revenue growth and 10.3% EPS growth over the past year. Over that period, revenue has moved from US$1.09 billion to US$1.23 billion, while EPS has shifted from US$1.49 to US$1.64, giving investors a clearer read on how the current quarter fits into the last year of results. With net margin...

Navitas Semiconductor (NVTS) kicked off Q1 2026 with revenue of US$8.6 million and a basic EPS loss of US$0.15, while over the trailing twelve months it posted revenue of US$40.5 million and a basic EPS loss of US$0.62. Over recent quarters the company has seen revenue move from US$14.0 million and a basic EPS loss of US$0.09 in Q1 2025 to US$7.3 million with a basic EPS loss of US$0.14 in Q4 2025. This frames a story where topline growth expectations and margin pressure are pulling in...

BrightView Holdings (BV) opened Q2 2026 with revenue of US$702.9 million and a basic EPS loss of US$0.08, while trailing 12 month figures show revenue of about US$2.7 billion and a small net loss of US$4.7 million. Over recent quarters, revenue has moved from US$662.5 million in Q2 2025 to US$702.9 million in Q2 2026, with EPS swinging between a loss of US$0.20 in Q1 2025 and a profit of US$0.16 in Q3 2025 before returning to a loss this quarter. This sets up a mixed picture for margins and...

Arista Networks (ANET) has opened 2026 with Q1 revenue of US$2.7 billion and basic EPS of US$0.81, setting the tone for how the rest of the year may unfold. Over recent quarters the company has seen revenue move from US$2.0 billion in Q1 2025 to US$2.7 billion in Q1 2026, while basic EPS has shifted from US$0.65 to US$0.81 across the same period, giving you a clear view of how the top and bottom line are tracking ahead of this latest report. With trailing net profit margins still near the...